Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
US6756360B1 · kind B1 · utility
20Cited by
14References
74Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 22, 1999 |
| Grant date | Jun 29, 2004 |
| Priority date | — |
| Expiry date | Dec 22, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/7076
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Pharmaceutical compositions containing an FBPase inhibitor and an insulin sensitizer are provided as well as methods for treating diabetes and diseases responding to increased glycemic control, an improvement in insulin sensitivity, a reduction in insulin levels, or an enhancement of insulin secretion.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.